Case Reports in Endocrinology

Case Reports in Endocrinology / 2012 / Article

Case Report | Open Access

Volume 2012 |Article ID 529730 | 5 pages | https://doi.org/10.1155/2012/529730

A Rare Corticotroph-Secreting Tumor with Coexisting Prolactin and Growth Hormone Staining Cells

Academic Editor: H. Kang
Received17 Oct 2012
Accepted29 Nov 2012
Published17 Dec 2012

Abstract

Pituitary adenomas can express and secrete different hormones. Expression of pituitary hormones in nonneoplastic pituitary cells is regulated by different transcription factors. Some pituitary adenomas show plurihormonal expression. The most commonly reported plurihormonal adenomas are composed of somatotrophs, lactotrophs, thyrotrophs and gonadotrophs. Pituitary adenomas composed of both corticotroph and somatolactotroph secreting cells are not common because transcription factors regulating the expression of these hormones are different. We report a rare case of pituitary adenoma with concomitant corticotroph, prolactin, and growth hormone staining cells, review literature on similar cases, and discuss possible biological mechanisms underlying these plurihormonal tumors.

1. Case Summary

A 52-year-old grocery store manager presented with symptoms of fatigue, poor libido, and erectile dysfunction for a two-year period. Onset was insidious and some of his symptoms were partially relieved by testosterone gel that was prescribed to him by his primary care doctor. He noted a 50 lb weight gain in a period of 6 months that prompted him to see an endocrinologist. In addition to the fatigue, he noted increasing muscle pain and proximal weakness over the past 6 months. He complained of increased ring and shoe size but it was difficult to clarify whether this was related to his generalized weight gain or specifically to his acral enlargement. On review of symptoms, he noted easy bruisability but denied breast enlargement or galactorrhea. His hypertension was well controlled with two medications and was not diagnosed with glucose intolerance. Clinical exam revealed a morbidly obese male with BMI of 48. His obesity was truncal, and he had disproportionately thin proximal musculature. Abdomen exam revealed 1 cm purple striae. His facial features were suggestive of cushingoid appearance. He did not have any definitive physical signs of acromegaly. His preoperative labs are summarized in Table 1, which were was conclusive for Cushing’s syndrome. He had mild elevation of prolactin (PRL), insulin-like growth factor (IGF-1) (Table 1). GH nadir after a 75 g glucose challenge was 0.36 ng/mL. MRI of the sella showed a pituitary microadenoma (5 mm) with a normal appearing stalk (Figure 1). Inferior petrosal sinus sampling confirmed the presence of pituitary source of ACTH hypersecretion. The patient underwent trans-sphenoidal resection of an unencapsulated tumor. The rest of the pituitary was carefully scrutinized with no evidence for additional tumors.


TestNormal rangePreoperativePostoperative

Testosterone (Total)300–890 pg/mL91195
Testosterone (Free)47–244 pg/mL17NA
Cortisol (AM)3.4–26.9 mcg/dL19.73.2
ACTH (AM)8–42 pg/mL8028
IGF-161–285 ng/mL323241
Prolactin2.1–17.7 ng/mL18.97.3
Free T40.8–1.8 ng/dL1.21.3
Cortisol (LDDST*)<1.8 mcg/dL10.8<1.0
Salivary cortisol (midnight)<50 ng/dL114
GH (Basal)0.01–0.97 ng/mL0.20<0.01
GH (75 g glucose load—30 min)0.21
GH (75 g glucose load—60 min)0.46
GH (75 g glucose load—120 min)0.36

*LDDST: Low-dose dexamethasone suppression test.

Histology of the resected tissue revealed one piece of tissue measuring 1 mm2 and that was composed of an adenoma with abundant relatively eosinophilic cytoplasm (Figure 2(a)). In addition, there were several smaller pieces of adenoma each measuring 0.2 mm in greatest dimension. These cells had less abundant and more basophilic cytoplasm (Figure 2(b)). Immunohistochemistry was performed using antibodies to PRL, GH, ACTH, TSH, LH, and FSH. All of the cells in the larger adenoma were immunoreactive with antibodies to PRL (A0569, Dako), and rare cells were positive to GH (A0570, Dako, Figure 2(c)). The cells of the small pieces of adenoma were ACTH positive (RB-9217-P0, Thermo-Fisher, Figure 2(d)). There was no overlap between the prolactin-positive and ACTH-positive cells. No cells labeled with antibodies to FSH (M3504, Dako), LH (M3502, Dako), or TSH (112A-18, Cell Marque). The patient was supplemented with hydrocortisone postoperatively. His PRL and IGF-1 levels normalized (Table 2).


Author and yearAge/sexSize of adenomaDominant clinical presentationAcromegaly evaluationCushings evaluationPattern of stains

Arita et al. 1991 [1]29/F1.6 cmAcromegaly and Cushing'sGH 92 ng/mL
ACTH 94 pg/mLDiffuse GH stainings and focal ACTH staining in the tumor tissue
Blevins et al. 1992 [2]40/F1.3 cm Acromegaly and Cushing'sGH 22 ng/mL
Nonsuppression of GH with OGTT
UFC 731 nmol/d (66–298)
Nonsuppression of UFC with 2 mg Dexamethasone
Two discrete cell groups each staining diffusely for GH and ACTH, respectively
Apel et al. 1994 [3]76/F2.2 cmAcromegalyGH 13.7 ng/mL (<5)
IGF-1 464 ng/L (116–270)
ACTH 6.5 pmol/L (<22)
PRL 25.8 mcg/L (<17.9)
Two discrete areas of GH and ACTH staining
Kovacs et al. 1998 [4]62/M>1 cm**AcromegalyGH 13.7 ng/mL (<5)
IGF-1: 973 ng/L (48–275)
Not availableMajority of cells displayed variable positivity for GH, whereas the minority of adenoma cells were strongly stain for ACTH; occasional cells positive for PRL
Mazarakis et al. 2001 [5]53/M1.5 cmAcromegalyGH 17.5 ng/mL
IGF-1 934 ng/mL
ACTH 29 pg/mL (<52)
No hypercortisolism documented
Chromophobic tumor, immunoreactive for GH focally admixed with hyperplastic PAS positive, and ACTH immunoreactive cells showing the electron microscopic features characteristic of corticotrophs
Kageyama et al. 2002 [6]45/F1.2 cmAcromegalyGH 20.9 ng/mL (<3.1)
IGF-1 650 ng/mL (46–282)
ACTH 91 pg/mL (<60)
Urine-free cortisol 403 mcg/d (40–140)
LDST-Cortisol Nonsuppression
HDST-cortisol suppression
2 distinct types of tumor cells, with either diffuse but faint GH-positive cells or sparse but distinct ACTH-stained cells; few PRL positive cells detected as well
Tsuchiya et al. 2006 [7]54/M1.2 cmAcromegalyGH: 31.5 ng/mL (<0.6)
IGF-1: 493 ng/mL (106–398)
ACTH: 53 pg/mL (7–56)
UFC: 45.6 mcg/d (<80.3)
LDST-Cortisol Nonsuppression
HDST-cortisol suppression
Diffuse GH and PRL staining and focal ACTH staining in the tumor tissue
Oki et al. 2009 [8]36/M>1 cm**AcromegalyGH 6.33 ng/mL
IGF-1: 1361.3 ng/mL (67–318)
ACTH 91.7 pg/mL
LDST-Cortisol Nonsuppression
HDST-cortisol suppression
Tumor cells with diffuse strong GH stain and focal staining with ACTH and TSH

**Clear evidence of macroadenoma on the MRI images, size details not provided in the case reports.
Values in parenthesis indicate normal ranges.
UFC: urine-free cortisol.
LDST: low-dose dexamethasone test (0.5 or 1 mg).
HDST: high-dose dexamethasone test (8 mg).

2. Discussion

Pituitary adenomas can express and secrete different hormones. Expression of pituitary hormones in nonneoplastic pituitary cells is regulated by different transcription factors. Pituitary-specific positive transcription factor 1 (PIT-1) regulates expression of GH, PRL, and TSH, and the steroidogenic factor 1 (STF-1) and endothelial transcription factor GATA 2 regulate expression of LH and FSH. ACTH expression is regulated by tumor homeobox transcription factor19 (TBX 19, also known as TPIT) [9]. Some pituitary adenomas show plurihormonal expression. The most commonly reported plurihormonal adenomas coexpress growth hormone (GH), prolactin (PRL), and/or thyroid stimulating hormone (TSH) or luteinizing hormone (LH) and follicle-stimulating (FSH) [10]. In view of the transcription factors that regulate the synthesis of the individual hormones, this finding is not surprising.

Plurihormonal tumors are either monomorphous (different hormones expressed from a single cell type or plurimorphous (different hormonal expression from different cells) [1113]. Our review of the literature (English language only) revealed few case reports of plurihormonal tumors with concomitant presence of ACTH and PRL/GH staining tumor cells [18, 14]. Details of clinical presentation and staining pattern of eight cases are listed in Table 2. In contrast to the previously published cases, where the tumor was a macroadenoma and the predominant clinical presentation was acromegaly, our patient had a microadenoma and dominant clinical presentation was Cushing’s disease.

Diagnosis of plurihormonal tumors relies on immunohistochemistry demonstrating significant and specific immunoreactivity to unrelated hormones using specific antisera. The case we report clearly had two histologically distinct populations of cells with evidence of different immunohistochemical hormonal expression. We have excluded the common pitfalls for misdiagnosis of plurihormonality. The histology of the specimen removed from the patient in our case showed only adenoma and did not include any tissue recognizable as entrapped normal adenohypophysis. The pattern of immunoreactivity for ACTH, PRL, and GH in the specimen was nonoverlapping and supports the interpretation that the antibodies used for detection were specific (Figure 2). It is impossible to conclude whether the expression of PRL and GH in one portion of the specimen influenced the clinical presentation of our patient. Although our patient did have marginally elevated PRL and IGF-1 levels, their clinical significance is uncertain.

The pathogenesis of plurimorphous plurihormonal tumors is hypothesized to be as a result of neoplastic transformation of two different cell lines or transdifferentiation of a once tumor cell line into a different hormone-producing cell line [9, 12, 15]. The possibility of tumors developing from noncommitted stem cells in the pituitary also has been suggested [15]. We did not perform an electron microscopy or a transcription factor analysis in our case, which limits further speculation on the original tumor cell line. Further work is required to elucidate the role of specific factors and the molecular mechanisms contributing to normal and abnormal pituitary development.

Conflict of Interests

The authors have no conflict of interests.

References

  1. K. Arita, T. Uozumi, S. Kuwabara et al., “A case of pituitary adenoma producing both growth hormone (GH) and adrenocorticotropic hormone (ACTH),” Endocrinologia Japonica, vol. 38, no. 3, pp. 271–278, 1991. View at: Google Scholar
  2. L. S. Blevins Jr., G. S. Hall, D. H. Madoff, E. R. Laws, and G. S. Wand, “Case report: acromegaly and Cushing's disease in a patient with synchronous pituitary adenomas,” American Journal of the Medical Sciences, vol. 304, no. 5, pp. 294–297, 1992. View at: Google Scholar
  3. R. L. Apel, R. J. Wilson, and S. L. Asa, “A composite somatotroph-corticotroph pituitary adenoma,” Endocrine Pathology, vol. 5, no. 4, pp. 240–246, 1994. View at: Publisher Site | Google Scholar
  4. K. Kovacs, E. Horvath, L. Stefaneanu et al., “Pituitary adenoma producing growth hormone and adrenocorticotropin: a histological, immunocytochemical, electron microscopic, and in situ hybridization study,” Journal of Neurosurgery, vol. 88, no. 6, pp. 1111–1115, 1998. View at: Google Scholar
  5. N. Mazarakis, G. Kontogeorgos, K. Kovacs, E. Horvath, N. Borboli, and G. Piaditis, “Composite somatotroph—ACTH-immunoreactive pituitary adenoma with transformation of hyperplasia to adenoma,” Pituitary, vol. 4, no. 4, pp. 215–221, 2001. View at: Publisher Site | Google Scholar
  6. K. Kageyama, T. Nigawara, Y. Kamata et al., “A multihormonal pituitary adenoma with growth hormone and adrenocorticotropic hormone production, causing acromegaly and Cushing disease,” American Journal of the Medical Sciences, vol. 324, no. 6, pp. 326–330, 2002. View at: Publisher Site | Google Scholar
  7. K. Tsuchiya, K. Ohta, T. Yoshimoto, M. Doi, H. Izumiyama, and Y. Hirata, “A case of acromegaly associated with subclinical Cushing's disease,” Endocrine Journal, vol. 53, no. 5, pp. 679–685, 2006. View at: Publisher Site | Google Scholar
  8. K. Oki, K. Yamane, Y. Oda et al., “Combined acromegaly and subclinical Cushing disease related to high-molecular-weight adrenocorticotropic hormone: case report,” Journal of Neurosurgery, vol. 110, no. 2, pp. 369–373, 2009. View at: Publisher Site | Google Scholar
  9. S. Melmed, “Pathogenesis of pituitary tumors,” Nature Reviews Endocrinology, vol. 7, no. 5, pp. 257–266, 2011. View at: Publisher Site | Google Scholar
  10. D. J. McComb, T. A. Bayley, E. Horvath, K. Kovacs, and I. A. Kourides, “Monomorphous plurihormonal adenoma of the human pituitary. A histologic, immunocytologic and ultrastructural study,” Cancer, vol. 53, no. 7, pp. 1538–1544, 1984. View at: Google Scholar
  11. N. Y. Y. Al-Brahim and S. L. Asa, “My approach to pathology of the pituitary gland,” Journal of Clinical Pathology, vol. 59, no. 12, pp. 1245–1253, 2006. View at: Publisher Site | Google Scholar
  12. S. L. Asa and S. Ezzat, “The pathogenesis of pituitary tumors,” Annual Review of Pathology, vol. 4, pp. 97–126, 2009. View at: Publisher Site | Google Scholar
  13. S. L. Asa, “Practical pituitary pathology: what does the pathologist need to know?” Archives of Pathology and Laboratory Medicine, vol. 132, no. 8, pp. 1231–1240, 2008. View at: Google Scholar
  14. F. Salehi, S. Cohen, L. V. Syro et al., “Plurihormonality in pituitary adenomas associated with acromegaly,” Endocrine Pathology, vol. 17, no. 3, pp. 291–296, 2006. View at: Publisher Site | Google Scholar
  15. K. Kovacs, E. Horvath, S. L. Asa, L. Stefaneanu, and T. Sano, “Pituitary cells producing more than one hormone: human pituitary adenomas,” Trends in Endocrinology and Metabolism, vol. 1, no. 2, pp. 104–107, 1989. View at: Publisher Site | Google Scholar

Copyright © 2012 Subramanian Kannan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

1952 Views | 919 Downloads | 3 Citations
 PDF  Download Citation  Citation
 Download other formatsMore
 Order printed copiesOrder

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19.